150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks

150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks

150 mg bococizumab injected subcutaneously every 2 weeks for a duration of 52 weeks
Bococizumab: PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

Bococizumab

150 mg placebo injected subcutaneously every 2 weeks for a duration of 52 weeks
Placebo

Placebo

Total

Sex: Female, Male

Race/Ethnicity, Customized

Region of Enrollment

Absolute CD4 T cell

The primary endpoint for the study is the percent change from baseline in fasting LDL-C at week 12.

Change of LDL-C From Baseline to Week 12

The primary endpoint for the study is the percent change from baseline in fasting total Lp(a) at week 12.

Change in Lp(a) From Entry to Week 12

Overall Study

Priscilla Hsue, PI

Dyslipidemia

Cardiovascular Disease

PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.

San Francisco General Hospital

Quest Clinical Research

San Francisco Veteran's Affair Medical Center

Bococizumab HIV Evaluation (B-HIVE) Study

Bococizumab HIV Evaluation (B-HIVE) Study: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Bococizumab, a PCSK9 Inhibitor, in HIV-Infected Subjects

Priscilla Hsue, MD

Principal Investigator

University of California, San Francisco

Pfizer

Patients with acute coronary syndrome with ST elevation and fibrinogen receiving a dose of 400 mg every 24 hours of Bezafibrate in addition to conventional anti-ischemic treatment

Patients with acute coronary syndrome with ST elevation and hyperfibrinogenemia who received only conventional anti-ischemic treatment

Acute Myocardial Infarction

Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy

Bezafibrate

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Early Effect Of Bezafibrate On Fibrinogen Levels, Inflammatory Response And Clinical Impact, In Patients With ST Elevation Acute Myocardial Infarction

PT-Fibrinogen HS Plus kit (Beckman Coulter, Brea, CA) to determine prothrombin time and fibrinogen and to evaluate extrinsic pathway of coagulation in citrated human plasma using an auto-analyzer ACL-800 (Cobas, Roche Diagnostics, Indianapolis, IN) where fibrinogen levels are determined through turbidimetry.

Concentration of cytokines (IL-8, IL-1β, IL-6, IL-10, TNF e IL-12) measured by ELISA system (Biosource)

angina, reinfarction, heart failure, death, and combined endpoints

Any side effect that comes with the intake of bezafibrate

Maria Alejandra Madrid Miller

Head of the Division of Health Research, UMAE Hospital de Cardiologia, Centro Médico Nacional Siglo XXI, IMSS, México, D.F.

Instituto Mexicano del Seguro Social

High-Risk Cancer

Fenretinide

European Institute of Oncology

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Breast Cancer Prevention With Fenretinide in Young Women at Genetic and Familil Risk. A Phase III Randomized Clinical Trial

The aim of the proposed trial is to assess the efficacy of fenretinide, (4 hydroxyphenilretinamide, 4-HPR), a vitamin A derivative, in reducing the incidence of breast cancer (BC) in healthy young premenopausal women at increased familial/genetic risk for BC (i.e. BRCA1 or BRCA2 mutation carriers or subjects at high risk of being carriers). The primary endpoint is the incidence of invasive BC and ductal intraepithelial neoplasia (DIN), histologically diagnosed.

Incidence of other non-invasive breast disorders, ovarian cancers and other cancers.
Early intermediate biomarkers of efficacy after 12, 36, and 60 months of treatment. We will also evaluate the percent change in circulating biomarkers of the IGF system, androgens, retinol binding protein (RBP-4), insulin, blood glucose and VEGF, after 12, 36 and 60 months of treatment.

urticaria/triglyceride

Bococizumab HIV Evaluation (B-HIVE) Study

Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction

Fenretinide in Healthy Young Women at Genetic and Familial Risk

Täydellisin lääketieteellinen tietokanta tieteen tukemana